Work

Abstract PS2-04-29: Parp inhibitors use in patients in germline palb2 or somatic brca1/2 mutations carriers with metastatic breast cancer: real life data from the esme database

Year: 2026

Type: conference-abstract

Source: Clinical Cancer Research

DOI: 10.1158/1557-3265.sabcs25-ps2-04-29

Authors: P. ROTTIER, L. CHALTIEL, Z. NEVIERE, W. JACOT, A. MAILLIEZ, F. DALENC, T. BACHELOT, E. BRAIN, V. MASSARD, B. SAUTEREY, T. GRINDA, C. BAILLEUX, M. ARDENOS, L. BOSQUET, G. EMILE

Institutions: Centre François Baclesse, Institut universitaire du cancer de Toulouse Oncopole, Institut Regional du Cancer de Montpellier, Centre Oscar Lambret, Centre Léon Bérard, Institut Curie, Institut de Cancérologie de Lorraine, Institut de Cancérologie de l'Ouest, Institut Gustave Roussy, Fondation Gustave Roussy, Centre Antoine Lacassagne, Institut Bergonié, UniCancer Group

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7130714558

Cites:

Cited by:

Related to: